JP2002053555A5 - - Google Patents

Download PDF

Info

Publication number
JP2002053555A5
JP2002053555A5 JP2001164523A JP2001164523A JP2002053555A5 JP 2002053555 A5 JP2002053555 A5 JP 2002053555A5 JP 2001164523 A JP2001164523 A JP 2001164523A JP 2001164523 A JP2001164523 A JP 2001164523A JP 2002053555 A5 JP2002053555 A5 JP 2002053555A5
Authority
JP
Japan
Prior art keywords
ethyl
adamantyl
pyridyl
propyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001164523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002053555A (ja
JP3867196B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2001164523A priority Critical patent/JP3867196B2/ja
Priority claimed from JP2001164523A external-priority patent/JP3867196B2/ja
Publication of JP2002053555A publication Critical patent/JP2002053555A/ja
Publication of JP2002053555A5 publication Critical patent/JP2002053555A5/ja
Application granted granted Critical
Publication of JP3867196B2 publication Critical patent/JP3867196B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001164523A 2000-05-31 2001-05-31 TNF−α産生阻害物質 Expired - Fee Related JP3867196B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001164523A JP3867196B2 (ja) 2000-05-31 2001-05-31 TNF−α産生阻害物質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-162945 2000-05-31
JP2000162945 2000-05-31
JP2001164523A JP3867196B2 (ja) 2000-05-31 2001-05-31 TNF−α産生阻害物質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006140241A Division JP4482735B2 (ja) 2000-05-31 2006-05-19 TNF−α産生阻害物質

Publications (3)

Publication Number Publication Date
JP2002053555A JP2002053555A (ja) 2002-02-19
JP2002053555A5 true JP2002053555A5 (OSRAM) 2006-07-20
JP3867196B2 JP3867196B2 (ja) 2007-01-10

Family

ID=18666780

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2001164523A Expired - Fee Related JP3867196B2 (ja) 2000-05-31 2001-05-31 TNF−α産生阻害物質
JP2006140241A Expired - Fee Related JP4482735B2 (ja) 2000-05-31 2006-05-19 TNF−α産生阻害物質
JP2009283084A Pending JP2010059204A (ja) 2000-05-31 2009-12-14 TNF−α産生阻害物質
JP2009283085A Pending JP2010059205A (ja) 2000-05-31 2009-12-14 TNF−α産生阻害物質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006140241A Expired - Fee Related JP4482735B2 (ja) 2000-05-31 2006-05-19 TNF−α産生阻害物質
JP2009283084A Pending JP2010059204A (ja) 2000-05-31 2009-12-14 TNF−α産生阻害物質
JP2009283085A Pending JP2010059205A (ja) 2000-05-31 2009-12-14 TNF−α産生阻害物質

Country Status (15)

Country Link
US (5) US7098226B2 (OSRAM)
EP (4) EP1568692B1 (OSRAM)
JP (4) JP3867196B2 (OSRAM)
KR (2) KR100880698B1 (OSRAM)
CN (3) CN1284771C (OSRAM)
AT (4) ATE374186T1 (OSRAM)
AU (3) AU2001260674B2 (OSRAM)
CA (2) CA2409741C (OSRAM)
CY (1) CY1107089T1 (OSRAM)
DE (4) DE60140495D1 (OSRAM)
DK (1) DK1302461T3 (OSRAM)
ES (4) ES2339141T3 (OSRAM)
NO (2) NO324472B1 (OSRAM)
PT (1) PT1302461E (OSRAM)
WO (1) WO2001092229A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140495D1 (de) * 2000-05-31 2009-12-24 Santen Pharmaceutical Co Ltd 1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen
WO2003045367A1 (en) * 2001-11-30 2003-06-05 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US20040033986A1 (en) 2002-05-17 2004-02-19 Protopopova Marina Nikolaevna Anti tubercular drug: compositions and methods
US7456222B2 (en) 2002-05-17 2008-11-25 Sequella, Inc. Anti tubercular drug: compositions and methods
CN101404986B (zh) 2002-05-17 2011-09-28 赛奎拉公司 用于诊断和治疗感染性疾病的组合物和制药方法
EP1670314A4 (en) 2003-09-05 2009-02-25 Sequella Inc METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
WO2005102332A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 変形性関節症治療剤
WO2005102331A1 (ja) * 2004-04-27 2005-11-03 Santen Pharmaceutical Co., Ltd. 骨粗鬆症治療剤
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006035759A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 呼吸器疾患治療剤
WO2006035760A1 (ja) * 2004-09-27 2006-04-06 Santen Pharmaceutical Co., Ltd. 皮膚疾患治療剤
WO2006043518A1 (ja) * 2004-10-18 2006-04-27 Santen Pharmaceutical Co., Ltd. 神経疾患治療剤
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
AU2006203918B2 (en) * 2005-01-05 2011-05-19 Abbvie Inc. Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
CA2594098C (en) * 2005-01-05 2014-04-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8562629B2 (en) * 2006-10-24 2013-10-22 Arthrocare Corporation Suture device having selective needle actuation and related method
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
WO2009020603A2 (en) * 2007-08-08 2009-02-12 The Scripps Research Institute Upp amphiphilic alpha-helix mimetics
WO2009051151A1 (ja) 2007-10-16 2009-04-23 Santen Pharmaceutical Co., Ltd. Trpv1媒介性疾患治療剤
WO2010047361A1 (ja) 2008-10-22 2010-04-29 参天製薬株式会社 腸管吸収性を改善する医薬組成物
RU2404157C1 (ru) * 2009-02-16 2010-11-20 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения n-(1-адамантилалкил)циклоалкиламинов
HRP20090186A2 (hr) 2009-03-31 2010-10-31 Institut Ruđer Bošković Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona
KR101231412B1 (ko) * 2009-12-29 2013-02-07 실트로닉 아게 실리콘 웨이퍼 및 그 제조 방법
BR112016011079A2 (pt) 2013-11-15 2017-12-05 Wistar Inst ?inibidores de ebna1 e seu método de uso?
MX2017014550A (es) 2015-05-14 2018-02-26 Wistar Inst Inhibidores del antigeno nuclear epstein-barr 1 (ebna1) y metodos que los utilizan.
CN112543634A (zh) 2018-05-17 2021-03-23 威斯达研究所 Ebna1抑制剂晶体形式及其制备和使用方法
CN110423216B (zh) * 2019-08-26 2021-01-05 浙江工业大学 一种2-(1-金刚烷甲酰胺基)乙基甲酸酯类化合物及其制备方法和应用
EP4605375A1 (en) * 2022-10-21 2025-08-27 eTheRNA immunotherapies NV Ionizable lipids

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2640055A (en) * 1951-01-06 1953-05-26 Warner Hudnut Inc Amides
CH500979A (de) * 1967-02-16 1970-12-31 Shimamoto Takio Verfahren zur Herstellung von Pyridinmethylcarbamaten
US3682922A (en) 1969-01-16 1972-08-08 Searle & Co N-acyl-n-{8 (n{40 ,n{40 -disubstituted amino)-alkyl{9 -1-adamantylmethylamines
US4597902A (en) 1981-05-20 1986-07-01 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas
US4724235A (en) 1981-05-20 1988-02-09 A. H. Robins Company, Incorporated N-(arylthioalkyl)-N'-(aminoalkyl)ureas useful in the treatment of arrhythmia
US4555515A (en) * 1985-02-25 1985-11-26 Stauffer Chemical Co. Pyridylpropyl carbamates as insect repellents
US5599944A (en) * 1987-03-24 1997-02-04 Bayer Aktiengesellschaft Intermediates for herbicidal sulphonylaminocarbonyltriazolinones having substituents which are bonded via sulphur
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
FR2664269B1 (fr) 1990-07-05 1992-10-02 Roussel Uclaf Nouveaux derives n-substitues d'alpha-mercapto alkylamines, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173506A (en) * 1990-08-16 1992-12-22 Schering Corporation N-(mercaptoalkyl)ureas and carbamates
CA2095429A1 (en) * 1990-11-06 1992-05-07 Paul E. Bender Imidazolidinone compounds
NZ242054A (en) * 1991-03-22 1993-11-25 British Tech Group Pyridine derivatives having a bridged alicyclic group; medicaments
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
WO1995029909A1 (en) * 1994-04-29 1995-11-09 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
WO1997008133A1 (fr) * 1995-08-22 1997-03-06 Japan Tobacco Inc. Composes amide et leur utilisation
GB9526560D0 (en) 1995-12-27 1996-02-28 Bayer Ag Use of 2-Amino-Heterocycles
GB9526558D0 (en) * 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
AU713676B2 (en) * 1996-01-16 1999-12-09 Merck & Co., Inc. Integrin receptor antagonists
IT1283637B1 (it) * 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
JP2001506257A (ja) * 1996-12-17 2001-05-15 藤沢薬品工業株式会社 Mmpまたはtnf阻害剤としてのピペラジン化合物
EP0903434B1 (de) * 1997-09-17 2002-11-27 Lenzing Aktiengesellschaft Verfahren zur Behandlung von Cellulosefasern
ATE228590T1 (de) 1997-09-17 2002-12-15 Chemiefaser Lenzing Ag Verfahren zur behandlung von cellulosefasern
JP3603177B2 (ja) 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
US6492370B1 (en) 1998-03-26 2002-12-10 Santen Pharmaceutical Co., Ltd. Urea derivatives and pharmaceutical compositions thereof
JP3472917B2 (ja) 1998-08-05 2003-12-02 参天製薬株式会社 含窒素芳香族複素環を有する新規ウレア誘導体
CN1147469C (zh) * 1998-08-05 2004-04-28 参天制药株式会社 带有芳香族含氮杂环的新型脲衍生物
EP1165531A1 (en) * 1999-03-19 2002-01-02 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'- 4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
WO2000061552A1 (en) * 1999-04-07 2000-10-19 Santen Pharmaceutical Co., Ltd. N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-α PRODUCTION INHIBITOR
DE29910780U1 (de) * 1999-06-21 1999-09-16 Hahn Schickard Ges Halte- und Betätigungsvorrichtung
DE60140495D1 (de) * 2000-05-31 2009-12-24 Santen Pharmaceutical Co Ltd 1-Ä(adamantyl)alkylÜ-3-Ä(pyridinyl)alkylÜHarnstoff-Verbindungen als TNF-.alpha Hemmer zur Behandlung von Autoimmunerkrankungen
WO2003045367A1 (en) * 2001-11-30 2003-06-05 Santen Pharmaceutical Co., Ltd. Angiogenesis inhibitor

Similar Documents

Publication Publication Date Title
JP2002053555A5 (OSRAM)
CN1878757A (zh) 吡啶酮衍生物及其应用
JP2005501120A5 (OSRAM)
JP2004512328A5 (OSRAM)
JP2006514626A5 (OSRAM)
JP2007016035A5 (OSRAM)
JP2004521087A5 (OSRAM)
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2006526031A5 (OSRAM)
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
JP2004506632A5 (OSRAM)
JP2004532209A5 (OSRAM)
JPH1036346A5 (OSRAM)
EP2039687A4 (en) THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST MULTIPLE SCLEROSIS
JP2005526081A5 (ja) 代謝型グルタメート受容体−5の二アリール置換テトラゾールモジュレータ
WO2002015662A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
EP1498411A4 (en) DICETOHYDRAZINE DERIVATIVE COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENTS
JP2006517939A5 (OSRAM)
WO2001074791A1 (en) Diazepane derivatives or salts thereof
JP2010511631A5 (OSRAM)
JP2010527993A5 (OSRAM)
JP2002030084A5 (OSRAM)
RU2003103780A (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
JP2004532828A5 (OSRAM)
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen